DK1364029T3 - Fusionsprotein, der omfatter hirudin og proinsulin eller insulin - Google Patents

Fusionsprotein, der omfatter hirudin og proinsulin eller insulin

Info

Publication number
DK1364029T3
DK1364029T3 DK02711847T DK02711847T DK1364029T3 DK 1364029 T3 DK1364029 T3 DK 1364029T3 DK 02711847 T DK02711847 T DK 02711847T DK 02711847 T DK02711847 T DK 02711847T DK 1364029 T3 DK1364029 T3 DK 1364029T3
Authority
DK
Denmark
Prior art keywords
proinsulin
hirudin
insulin
fusion protein
protein
Prior art date
Application number
DK02711847T
Other languages
English (en)
Inventor
Johann Ertl
Paul Habermann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1364029T3 publication Critical patent/DK1364029T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02711847T 2001-02-20 2002-02-08 Fusionsprotein, der omfatter hirudin og proinsulin eller insulin DK1364029T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10108212A DE10108212A1 (de) 2001-02-20 2001-02-20 Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände

Publications (1)

Publication Number Publication Date
DK1364029T3 true DK1364029T3 (da) 2006-05-08

Family

ID=7674913

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02711847T DK1364029T3 (da) 2001-02-20 2002-02-08 Fusionsprotein, der omfatter hirudin og proinsulin eller insulin

Country Status (19)

Country Link
EP (1) EP1364029B1 (da)
JP (1) JP4243104B2 (da)
KR (1) KR100858009B1 (da)
CN (1) CN100500853C (da)
AT (1) ATE314480T1 (da)
AU (1) AU2002231784B2 (da)
BR (1) BRPI0207394B8 (da)
CA (1) CA2438886C (da)
DE (2) DE10108212A1 (da)
DK (1) DK1364029T3 (da)
ES (1) ES2254658T3 (da)
HK (1) HK1065335A1 (da)
IL (1) IL157414A0 (da)
MX (1) MXPA03007114A (da)
NO (1) NO331271B1 (da)
NZ (1) NZ527643A (da)
PE (1) PE20020876A1 (da)
WO (1) WO2002068660A1 (da)
ZA (1) ZA200305869B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP5028551B2 (ja) 2003-11-21 2012-09-19 フェネックス インコーポレイテッド Sec系分泌によって改良された発現系
ES2707786T3 (es) 2004-01-16 2019-04-05 Pfenex Inc Expresión de proteínas de mamífero en Pseudomonas fluorescens
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
AU2008210538B2 (en) 2007-01-31 2013-06-06 Pelican Technology Holdings, Inc. Bacterial leader sequences for increased expression
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR101530395B1 (ko) 2007-04-27 2015-06-19 피페넥스 인크. 향상된 수율 및(또는) 품질로 이종 단백질을 발현하는 특정 균주를 동정하기 위해 미생물 숙주를 신속히 스크리닝하는 방법
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0907371A2 (pt) 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
NZ586589A (en) 2008-01-09 2012-04-27 Sanofi Aventis Deutschland Novel insulin analogues having an extremely delayed time-action profile
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2010038145A2 (en) * 2008-10-02 2010-04-08 Unitargeting Research As Kit for the optimisation of protein synthesis/secretion
DK2349324T3 (da) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland Kombination af et insulin og en glp-1-agonist
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト及びメチオニンを含む薬学的組成物
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Glp-1 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
ES2853935T3 (es) 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
WO2015089321A2 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004418A1 (fr) * 1984-03-27 1985-10-10 Transgene S.A. Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
AU648124B2 (en) * 1990-11-08 1994-04-14 Japan Energy Corporation Hirudine mutant, production thereof, anticoagulant, secretory vector, microorganism transformed by said vector, and production of product from said microorganism
WO1995009125A1 (en) * 1992-09-28 1995-04-06 Pehr Harold T Kicker latch for container closures
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP

Also Published As

Publication number Publication date
AU2002231784B2 (en) 2006-10-26
BRPI0207394B8 (pt) 2021-05-25
WO2002068660A1 (en) 2002-09-06
BRPI0207394B1 (pt) 2015-06-16
CA2438886C (en) 2013-07-23
NO20033673D0 (no) 2003-08-19
CN100500853C (zh) 2009-06-17
EP1364029A1 (en) 2003-11-26
JP2004518444A (ja) 2004-06-24
JP4243104B2 (ja) 2009-03-25
ATE314480T1 (de) 2006-01-15
NZ527643A (en) 2005-07-29
IL157414A0 (en) 2004-03-28
CA2438886A1 (en) 2002-09-06
DE10108212A1 (de) 2002-08-22
KR100858009B1 (ko) 2008-09-11
KR20030074842A (ko) 2003-09-19
EP1364029B1 (en) 2005-12-28
CN1529757A (zh) 2004-09-15
HK1065335A1 (en) 2005-02-18
ES2254658T3 (es) 2006-06-16
MXPA03007114A (es) 2003-11-18
DE60208343T2 (de) 2006-06-22
DE60208343D1 (de) 2006-02-02
NO20033673L (no) 2003-10-17
NO331271B1 (no) 2011-11-14
ZA200305869B (en) 2004-06-25
BR0207394A (pt) 2004-02-10
PE20020876A1 (es) 2002-11-05

Similar Documents

Publication Publication Date Title
DK1364029T3 (da) Fusionsprotein, der omfatter hirudin og proinsulin eller insulin
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
EE200100223A (et) Interferoon-beetaga sulandatud valgud ja nende kasutamine
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DE60325892D1 (de) Stellungs- und verwendungsverfahren
DK1427750T3 (da) Modificerede transferrin-fusionsproteiner
DK1699822T3 (da) IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
DK1453850T3 (da) EGVIII-endoglukanase og nukleinsyrer kodende for det samme
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
DK1346034T3 (da) von Willebrand-faktor (vWF) spaltende protease-polypeptid, nukleinsyre kodende for polypeptidet og anvendelse af polypeptidet
DK1481059T3 (da) Eukaryote signalsekvenser for polypeptidekspression og polypeptiddisplaybiblioteker
WO2005047459A3 (en) Sars nucleic acids, proteins, antibodies, and uses thereof
ATE450544T1 (de) Streptavidin-bindungspeptid
ATE323763T1 (de) Dna & protein bindende miniatur proteine
EP1558729A4 (en) QUICKLY REMOVED REPORTER FUSION PROTEINS
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
NO20005081D0 (no) Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
AU2002258630A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2003287108A1 (en) Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
AU2002257075A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2003016465A3 (en) Cell cycle regulator protein
IL204767A (en) Stable chimeric oligomeric proteins for denture and protease resistant